JNJ Press releases
News
Other news
Ribon Therapeutics Secures $65 Million Financing
Read full storyOther news
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
Read full storyOther news
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
Read full storyIn the media
Johnson & Johnson: The Leading Healthcare Group at the Forefront of Open Innovation
Read full storyOther news
TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases
Read full storyOther news
Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development
Read full storyPartner news
Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development
Read full storyIn the media
Michael Hübner – New Venture Lead, Johnson & Johnson Innovation Switzerland
Read full storyOther news
Datavant and Ciox Health Announce Merger, Creating the Largest Neutral and Secure Health Data Ecosystem
Read full storyOther news
entrinsic bioscience Secures $49 million in Financing to Accelerate Development and Commercialization of Next Generation Functional Ingredients and Active Pharmaceutical Ingredients
Read full storyOther news
Quest Diagnostics and Paige Form Collaboration to Advance AI-generated Pathology Insights to Improve Cancer Diagnosis and Care
Read full storyOther news
On Target Laboratories, Inc. Announces Results of Phase 3 Trial for Pafolacianine Sodium Injection for Intraoperative Illumination of Folate Receptor Positive Ovarian Cancer
Read full storyPartner news
Mestag Therapeutics announces collaboration with Janssen, focused on the discovery of novel fibroblast targets for the treatment of inflammatory disease
Read full storyOther news